VIP236 demonstrated positive signs of clinical activity, including tumor reduction, and an improved safety profile in heavily pretreated patients with metastatic solid tumors VIP943 pharmacokinetic (PK) data shows very little free payload in circulation, consistent with the favorable safety profile observed preclinically and clinically In preclinical studies, Vincerx’s next-generation effector chemistry improves the efficacy... Read More

PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, will host a virtual investor event reviewing preliminary clinical data from its Phase 1 dose-escalation study of VIP236 and provide an update on pipeline progress on Monday, April 8, 2024, at 2 PM PT.... Read More

VIP236, first-in-class small molecule-drug conjugate (SMDC), preliminary Phase 1 data and update on pipeline progress will be presented by management at a virtual investor event on April 8 at 2:00 PM PT Phase 1 trial ongoing for VIP943, a best-in-class anti-CD123 antibody-drug conjugate (ADC); preliminary data anticipated on or around the 2024 European Hematology Association (EHA) Annual Meeting; in addition, pharmacokinetic... Read More

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced it will present three posters at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, CA, from April 5 – 10, 2024. Vincerx will also share... Read More

Investigators from the National Institutes of Health (NIH) report 2 partial responses (PR) in 3 peripheral T-cell lymphoma (PTCL) patients and 1 PR in 2 double-hit diffuse large b-cell lymphoma (DH-DLBCL) patients in ongoing dose-escalation trial of enitociclib in combination with venetoclax and prednisone Vincerx remains on target to report early clinical data from lead VersAptx™ platform compounds, VIP236 (early 2024) and... Read More

Poster on VIP943, a novel CD123-targeted antibody-drug conjugate (ADC) from our VersAptx™ platform, showcases selectivity, activity, and safety of VIP943 Poster on VIP924, a first-in-class CXCR5-targeted ADC from our VersAptx platform, shows superior activity and safety compared with commercially available B-cell targeted ADCs PALO ALTO, Calif., Dec. 10, 2023 (GLOBE NEWSWIRE) - - Vincerx Pharma, Inc. (Nasdaq:... Read More

Phase 1 dose escalation for VIP943 - first antibody-drug conjugate (ADC) from VersAptx™, versatile and adaptable, next-generation bioconjugation platform - moves quickly into 2 nd cohort Phase 1 dose escalation for VIP236 - first-in-class small molecule-drug conjugate (SMDC) for treatment of solid tumors - progressing well with optimized dosing schedule Phase 1 dose escalation combination study for enitociclib in... Read More

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of... Read More

PALO ALTO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s CEO Ahmed Hamdy, M.D. and the Management Team will participate in a panel presentation and one-on-one investor meetings at the Cantor Fitzgerald Global Healthcare... Read More

PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that the first patient has been dosed in the Phase 1 trial evaluating VIP943 in patients with relapsed/refractory acute myeloid leukemia (R/R AML), myelodysplastic syndrome... Read More

Phase 1 trial expected to begin in early Q4 2023 VIP943 is Vincerx’ first candidate from next-generation ADC platform and its second IND clearance within 8 months, highlighting Vincerx’s development and regulatory expertise PALO ALTO, Calif., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through... Read More

IND Application filed for potential best-in-class ADC, VIP943; Phase 1 trial expected to begin Q4 2023 Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class SMDC Cash balance expected to support planned operations into late 2024 PALO ALTO, Calif., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of... Read More

Enrollment continues in Phase 1 dose escalation study for VIP236, a first-in-class α v β 3 small molecule drug conjugate (SMDC) for the treatment of solid tumors IND filing for VIP943, a next-generation antibody-drug conjugate (ADC), for treatment of CD123+ hematologic malignancies on track for mid-2023 Cash balance expected to support planned operations into late 2024 PALO ALTO, Calif., May 11, 2023 (GLOBE NEWSWIRE) --... Read More

PALO ALTO, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of VIP924 preclinical data at the 2023 American Association for Cancer Research (AACR) Annual Meeting. VIP924 consists of an anti-CXCR5 humanized monoclonal antibody with a... Read More

PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of preclinical data on novel integrin α v β 3 -targeted s mall molecule drug conjugates (SMDCs) at the American Association for Cancer Research (AACR) Annual Meeting. Vincerx’s... Read More

PALO ALTO, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today presented a poster of preclinical data of VIP236 monotherapy treatment in PDX and metastatic PDX mouse models across several tumor types at the 2023 American Association for Cancer Research... Read More

First cohort dosed in Phase 1 first-in-human dose-escalation study of VIP236, an α v β 3 small molecule drug conjugate (SMDC) in advanced solid tumors IND filing for antibody drug conjugate (ADC) VIP943 remains on track for mid-2023; expected to be in clinic in the second half 2023 Anticipate dosing first patient in Phase 1b combination study of enitociclib and approved Bruton tyrosine kinase (BTK) inhibitor in CLL in second... Read More

PALO ALTO, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced four poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held virtually and at the Orange County Convention Center in... Read More

PALO ALTO, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will present the company’s corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held... Read More

VIP236 is a first-in-class α V β 3 integrin binder SMDC with the potential to address a broad patient population across multiple solid tumor indications Preclinical studies with VIP236 demonstrated promising tumor regression in in vivo cancer models VIP236 first-in-human study in advanced or metastatic solid tumors anticipated to commence in Q1 2023 PALO ALTO, Calif., Dec. 13, 2022 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc.... Read More

In a multiple myeloma (MM) preclinical study, antitumor efficacy was observed with enitociclib as a monotherapy and in combination with several anti-MM agents Significant MYC downregulation was observed in patients with double-hit diffuse large B-cell lymphoma (DH-DLBCL) and other B-cell malignancies with a 30-mg dose level while maintaining a favorable safety profile Clinical trial to evaluate enitociclib in combination... Read More

Vincerx’s proprietary payload and linker technology and VIP943, a novel anti-CD123 antibody drug conjugate (ADC), demonstrated superiority with significant improved safety in non-human primates (NHP) when compared with Mylotarg™ (gemtuzumab ozogamicin) VIP943 demonstrated monotherapy activity in ex vivo AML models and in vivo activity with significant tumor regression in combination with venetoclax and azacitidine in an... Read More